ArticleExperimental cell research2013
Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.
Article in Experimental cell research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Review
- Identification of macrophage related gene in colorectal cancer patients and their functional roles.BMC medical genomics · 2021Article
- Article
- Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells.Journal of experimental & clinical cancer research : CR · 2020Review
- Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.American journal of physiology. Renal physiology · 2019Article
- Soft Tissue Sarcoma Cancer Stem Cells: An Overview.Frontiers in oncology · 2018Review
- Review
- Targeting histone methylation for colorectal cancer.Therapeutic advances in gastroenterology · 2017Review
- Epigenetics in Intestinal Epithelial Cell Renewal.Journal of cellular physiology · 2016Review
- miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.Scientific reports · 2016Article
- Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.Journal of the American Society of Nephrology : JASN · 2016Article
- Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Cancer Stem Cells: Dynamic Entities in an Ever-Evolving Paradigm.Biology and medicine (Aligarh) · 2015Article
- Common stemness regulators of embryonic and cancer stem cells.World journal of stem cells · 2015Review
- Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.Oncotarget · 2015Article
- DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis.Acta pharmaceutica Sinica. B · 2015Article
- The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.Journal of translational medicine · 2014Review
- Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.BMC cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Colorectal cancer is among the leading causes of cancer death in the USA. The polycomb repressive complex 2 (PRC2), including core components SUZ12 and EZH2, represents a key epigenetic regulator of digestive epithelial cell physiology and was previously shown to promote deleterious effects in a number of human cancers, including colon. Using colon cancer stem cells (CCSC) isolated from human primary colorectal tumors, we demonstrate that SUZ12 knockdown and treatment with DZNep, one of the most potent EZH2 inhibitors, increase apoptosis levels, marked by decreased Akt phosphorylation, in CCSCs, while embryonic stem (ES) cell survival is not affected. Moreover, DZNep treatments lead to increased PTEN expression in these highly tumorigenic cells. Taken together, our findings suggest that pharmacological inhibition of PRC2 histone methyltransferase activity may constitute a new, epigenetic therapeutic strategy to target highly tumorigenic and metastatic colon cancer stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.